PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
Table 4
Patients’ characteristics and association with PD-L1 (Dako22C3).
Characteristics
PD-L1 (Dako22C3)
value
<1% ()
1-49% ()
≥50% ()
Age, median (years)
65 (30-93)
66 (43-94)
66 (44-81)
≤65
28 (43.8%)
27 (42.2%)
9 (14.1%)
0.890
>65
25 (39.7%)
29 (46.0%)
9 (14.3%)
Gender
Male
30 (36.1%)
41 (49.4%)
12 (14.5%)
0.189
Female
23 (52.3%)
15 (34.1%)
6 (13.6%)
Histology
Adenocarcinoma
41 (46.6%)
36 (40.9%)
11 (12.5%)
0.759
SqCC
4 (25%)
9 (56.3%)
3 (18.8%)
Adenosquamous carcinoma
2 (40.0%)
2 (40.0%)
1 (20.0%)
NSCLC
6 (33.3%)
9 (50.0%)
3 (16.7%)
T
1
5 (62.5%)
3 (37.5%)
0 (0.0%)
0.566
2
10 (47.6%)
7 (33.3%)
4 (19.0%)
3
9 (45.0%)
10 (50.0%)
1 (5.0%)
4
28 (39.4%)
31 (43.7%)
12 (16.9%)
N
0
5 (50.0%)
4 (40.0%)
1 (10.0%)
0.031
1
7 (77.8%)
2 (22.2%)
0 (0.0%)
2
15 (62.5%)
6 (25.0%)
3 (12.5%)
3
26 (31.0%)
44 (52.4%)
14 (16.7%)
M
0
10 (45.5%)
7 (31.8%)
5 (22.7%)
0.306
1
43 (41.0%)
49 (46.7%)
13 (12.4%)
Stage
I/II
3 (60.0%)
1 (20.0%)
1 (20.0%)
0.568
III
7 (41.2%)
6 (35.3%)
4 (23.5%)
IV
43 (41.0%)
49 (46.7%)
13 (12.4%)
EGFR
Mutation
24 (49.0%)
21 (42.9%)
4 (8.2%)
0.264
Wild type
22 (36.1%)
29 (47.5%)
10 (16.4%)
ALK
Positive
1 (16.7%)
4 (66.7%)
1 (16.7%)
0.412
Negative
45 (44.1%)
44 (43.1%)
13 (12.7%)
PD-L1 (SP142 TC/IC)
<1%/<1%
43 (53.1%)
35 (43.2%)
3 (3.7%)
<0.001
Intermediate
4 (16.7%)
15 (62.5%)
5 (20.8%)
≥50%/>10%
1 (10.0%)
1 (10.0%)
8 (80.0%)
PD-L1 (Dako28-8)
<1%
41 (77.4%)
11 (20.8%)
1 (1.9%)
<0.001
1-49%
7 (17.5%)
31 (77.5%)
2 (5.0%)
≥50%
0 (0.0%)
6 (42.9%)
8 (57.1%)
Figures are numbers with percentages in parentheses, unless otherwise stated. The chi-squared test of independence: categorical variable. NSCLC: non-small cell lung cancer; TC: tumor cells; IC: immune cells.
